Cargando…
A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2
No vaccine against infection by SARS-CoV-2 yet exists. Treatment by hydroxychloroquine (HCQ) medication, among others, has been proposed. However, prophylactic HCQ medication has been little evaluated. We propose to use data from patients with rheumatic diseases (RA, SLR) who have been chronically t...
Autor principal: | Musca, Serban C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438534/ https://www.ncbi.nlm.nih.gov/pubmed/32903552 http://dx.doi.org/10.3389/fmed.2020.00490 |
Ejemplares similares
-
Hydroxychloroquine in rheumatic autoimmune disorders and beyond
por: Nirk, Eliise Laura, et al.
Publicado: (2020) -
COVID-19 and hydroxychloroquine: Let the available data speak for themselves
por: Paliani, Ugo, et al.
Publicado: (2020) -
Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Singh, Dilpreet K, et al.
Publicado: (2019) -
Since you have been away
Publicado: (1972) -
Comment on: Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine
por: Pareek, Anil, et al.
Publicado: (2019)